Trial Profile
Phase I study of ARM 210 (S48168) for the treatment of Duchenne muscular dystrophy
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2014
Price :
$35
*
At a glance
- Drugs ARM 210 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors ARMGO Pharma; Servier
- 10 Dec 2014 New trial record
- 04 Dec 2014 This trial is expected to begin in 2015 after receipt of input from regulatory agencies, according to a media release from ARMGO Pharma and Servier.